Trial Profile
A Belgian Observational Non-Interventional Study Evaluating Effect of Certolizumab Pegol (CZP) Treatment on Workplace and Household Productivity Over 52 weeks in Patients with Rheumatoid Arthritis (RA) in Real-World Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2016
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2016 New trial record
- 02 Nov 2016 Results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.